Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia, Diabetes Mellitus
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.
- Trial name
- NCT00236379
- Testing
- Olanzapine, Risperidone
- Volunteers
- 59 people
- Sponsor
- Janssen, LP
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Schizophrenia, Schizoaffective Disorder
Shared Decision Making for Antipsychotic Medications
This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05416658
- Testing
- The Antipsychotic Medication Decision Aid (APM-DA)
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Diabetes Mellitus, Type 2, Severe Mental Disorder
Improving Diabetes Outcomes for People With Severe Mental Illness (SMI)
This study aims to identify the determinants of diabetes and to explore variation in diabetes outcomes for people with severe mental illness (schizophrenia, schizoaffective disorder and bipolar disorder) in order to develop…
- Trial name
- EMERALD (NCT03534921)
- Where
- United Kingdom
- Volunteers
- 46,564 people
- Sponsor
- University of York
Schizophrenia
Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia
This study will compare the effectiveness of three treatments in improving medication adherence, symptoms, and function in people with schizophrenia.
- Trial name
- NCT00455663
- Testing
- Cognitive Adaptation Training, Pharm-Cognitive Adaptation Training, Treatment as usual
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Schizoaffective Disorder
The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
It has been suggested that patients with schizophrenia smoke in order to produce amelioration of dysfunctional dopaminergic pathways allowing them to experience pleasure and satisfaction and overcome anhedonia.
- Trial name
- NCT00373126
- Testing
- transdermal nicotine patch
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia, Dual Diagnosis
Alcoholism and Schizophrenia: Effects of Clozapine
The purpose of this study is to examine the short - term effects of clozapine on alcohol use in persons with schizophrenia and an alcohol use disorder.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00169026
- Testing
- Clozapine versus typical (conventional) and atypical antipsychotic medications
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Health Evaluation of Abilify Long-term Therapy
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment.
- Trial name
- HEALTH (NCT00520650)
- Testing
- Aripiprazole
- Where
- 9 sites in Taiwan
- Volunteers
- 245 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Healthy, Schizophrenia
Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients
Brain cells communicate with each other by releasing chemicals called neurotransmitters. In order for brain cells to transfer information, one cell will release a neurotransmitter that will be recognized by a receptor located on…
- Trial name
- NCT00001320
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
The purpose of this study is to 1) determine whether the effect on QT interval corrected (QTcLD) for heart rate using the population specified linear derived method at steady state is comparable between 12 mg paliperidone…
- Trial name
- NCT00791622
- Testing
- Paliperidone ER
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizophrenia and Disorders With Psychotic Features
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the…
- Conditions
- Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
- Trial name
- NCT02307396
- Testing
- Olanzapine, Amisulpride, Risperidone
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Technical University of Munich
Schizophrenia, Schizoaffective Disorder
A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
This study proposes to examine the effect of atomoxetine on quality of life and negative symptoms such as social withdrawal, lack of interest in things, lack of thought content, flat emotions, slowed body movements and lack of…
- Trial name
- NCT00222794
- Testing
- Atomoxetine (Strattera)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Pittsburgh
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Schizoaffective Disorder, Schizophrenia
A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
The purpose of this study is to compare three strategies for switching patients with schizophrenia or schizoaffective disorder to the atypical antipsychotic, risperdone, after they have been unsuccessfully treated with another…
- Trial name
- NCT00378183
- Testing
- risperidone
- Volunteers
- 120 people
- Sponsor
- Janssen, LP
Psychotic Disorders, Depressive Disorder, Major
Treatment of Schizoaffective Disorder Using Mifepristone
This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
- Conditions
- Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
- Trial name
- NCT00725270
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Schizophrenia and Schizoaffective Disorder
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
- Trial name
- NCT00347425
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- 122 sites in United States, Argentina and 7 more
- Volunteers
- 286 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
A Pharmacokinetic Study of Paliperidone ER
Background Paliperidone is an active metabolite of risperidone, both of which are antipsychotic agents for treatment of schizophrenia and related psychotic disorders.
- Trial name
- NCT02433717
- Testing
- Paliperidone ER
- Where
- 2 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Psychosis, Schizophrenia
Service User and Staff Views on Digital Remote Monitoring for Psychosis
Psychosis is a severe mental health problem. Symptoms of psychosis include hallucinations (e.g. hearing voices that others cannot hear) and delusions (unusual, often troubling beliefs).
- Conditions
- Psychosis, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT05670197
- Testing
- No intervention. Participants will take part in a qualitative interview
- Where
- 6 sites in United Kingdom
- Volunteers
- 118 people
- Sponsor
- Manchester Academic Health Science Centre
Schizophrenia, Psychotic Disorders
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
The purpose of this study is to assess the usefulness of the Risperdal® Consta® Treatment Guidebook in helping the doctor switch the adult patient from taking risperidone tablets daily by mouth to taking long-acting risperidone…
- Trial name
- NCT00236548
- Testing
- risperidone
- Volunteers
- 1 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.